FOS and neoplasm: Co‐treatment with dacarbazine and statins significantly inhibited tumor growth and metastasis by suppressing the RhoA/RhoC/LIM domain kinase/serum response factor/c‐Fos signaling pathway, while enhancing the expression of p53, p21, p27, cleaved caspase‐3, and cleaved PARP1 in vivo.